LOH11CR2A Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | O00534 |
---|---|
Clone Names | 81202077 |
Gene ID | 4013 |
---|---|
Other Names | von Willebrand factor A domain-containing protein 5A, Breast cancer suppressor candidate 1, BCSC-1, Loss of heterozygosity 11 chromosomal region 2 gene A protein, VWA5A, BCSC1, LOH11CR2A |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP8651a was selected from the N-term region of human LOH11CR2A. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | VWA5A |
---|---|
Synonyms | BCSC1, LOH11CR2A |
Function | May play a role in tumorigenesis as a tumor suppressor. Altered expression of this protein and disruption of the molecular pathway it is involved in, may contribute directly to or modify tumorigenesis. |
Tissue Location | Expressed at low level in many tissues. Not expressed in 80% of tumor cell lines tested |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
LOH11CR2A may play a role in tumorigenesis as a tumor suppressor. Altered expression of this protein and disruption of the molecular pathway it is involved in, may contribute directly to or modify tumorigenesis.
References
Zhou,Y.Q., et.al., Cancer Sci. 100 (10), 1817-1822 (2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.